Press releases

January 7, 2019 Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyond
- Delivered more than 302,000 samples, generating revenue of more than $144 million in 2018 -
- Provides 2019 guidance of more than 500,000 sample test volume and more than $220 million in 2019 revenue - Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, announced preliminary unaudited full-year 2018 results showing triple-digit growth driven by strong commercial execution, test menu expansion and the accelerating use of genetics in healthcare. "We envisioned a world in which genetic information can inform healthcare decisions throughout every stage of life, and that is rapidly becoming a reality. Invitae's strong 2018 results are indicative of this shift as we bring genetics into mainstream medicine with high-quality, comprehensive, affordable testing," said Sean George, co-founder and chief executive officer of Invitae. "With another year of unprecedented growth behind us, we intend to build on this momentum in 2019, growing an even larger network
Read more


The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.


This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements
NYSE: NVTA 15.01 +0.07 +0.47% Volume: 236,084 20 minute delay January 22, 2019

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *

Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103